Reinfection with SARS-CoV-2: Implications for Vaccines

Abstract Infection with SARS-CoV-2 has become pandemic and the duration of protective immunity to the virus is unknown. Cases of persons reinfected with the virus are being reported with increasing frequency. At present it is unclear how common reinfection with SARS-CoV-2 is and how long serum antibodies and virus-specific T cells persist after infection. For many other respiratory virus infections, including influenza and the seasonal coronaviruses that cause colds, serum antibodies persist for only months to a few years and reinfections are very common. Here we review what is known about the duration of immunity and reinfection with coronaviruses, including SARS-CoV-2, and well as the duration of immunity to other viruses and virus vaccines. These findings have implications for the need of continued protective measures and for vaccines for persons previously infected with SARS-CoV-2.

[1]  D. Stuart,et al.  Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.

[2]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[3]  M. V. van Zelm,et al.  Rapid and lasting generation of B-cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 disease and convalescence , 2020, medRxiv.

[4]  D. Stuart,et al.  Antibodies to SARS-CoV-2 are associated with protection against reinfection , 2020, medRxiv.

[5]  Bjoern Peters,et al.  Immunological memory to SARS-CoV-2 assessed for up to eight months after infection , 2020, bioRxiv.

[6]  P. Bieniasz,et al.  Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients , 2020, The Journal of infectious diseases.

[7]  C. Cordon-Cardo,et al.  Robust neutralizing antibodies to SARS-CoV-2 infection persist for months , 2020, Science.

[8]  M. Malim,et al.  Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans , 2020, Nature Microbiology.

[9]  L. Poon,et al.  Serologic Responses in Healthy Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020 , 2020, Emerging infectious diseases.

[10]  H. Goossens,et al.  Seasonal coronavirus protective immunity is short-lasting , 2020, Nature Medicine.

[11]  A. Gylfason,et al.  Humoral Immune Response to SARS-CoV-2 in Iceland , 2020, The New England journal of medicine.

[12]  K. To,et al.  COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Bloom,et al.  Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate , 2020, Journal of Clinical Microbiology.

[14]  Lisa E. Gralinski,et al.  A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2 , 2020, Cell.

[15]  M. Germain,et al.  Risk of transmission of severe acute respiratory syndrome coronavirus 2 by transfusion: A literature review , 2020, Transfusion.

[16]  J. Tang,et al.  Setting the criteria for SARS-CoV-2 reinfection – six possible cases , 2020, Journal of Infection.

[17]  P. Bieniasz,et al.  Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents , 2020, medRxiv.

[18]  Angelo Carfì,et al.  Persistent Symptoms in Patients After Acute COVID-19. , 2020, JAMA.

[19]  L. Moreno-Fierros,et al.  Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity? , 2020, Expert opinion on biological therapy.

[20]  J. Shaman,et al.  Direct Observation of Repeated Infections With Endemic Coronaviruses , 2020, medRxiv.

[21]  Gavin J. D. Smith,et al.  Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2 , 2020, Emerging microbes & infections.

[22]  K. Walters,et al.  Influenza A Reinfection in Sequential Human Challenge: Implications for Protective Immunity and "Universal" Vaccine Development. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  P. T. Ten Eyck,et al.  Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses , 2017, Science Immunology.

[24]  Kyoung-Ho Song,et al.  MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015 , 2017, Emerging infectious diseases.

[25]  S. Perlman,et al.  Antibody Response and Disease Severity in Healthcare Worker MERS Survivors , 2016, Emerging infectious diseases.

[26]  A. Iwasaki.  Exploiting Mucosal Immunity for Antiviral Vaccines. , 2016, Annual review of immunology.

[27]  N. Grassly,et al.  Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge , 2012, PLoS pathogens.

[28]  S. Plotkin.  Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.

[29]  Nichole E Carlson,et al.  Duration of humoral immunity to common viral and vaccine antigens. , 2007, The New England journal of medicine.

[30]  M. Chan-yeung,et al.  Longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance , 2006, Respirology.

[31]  R. Ahmed,et al.  Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity , 1996, Trends in Microbiology.

[32]  E. Walsh,et al.  Immunity to and frequency of reinfection with respiratory syncytial virus. , 1991, The Journal of infectious diseases.

[33]  D. Tyrrell,et al.  The time course of the immune response to experimental coronavirus infection of man , 1990, Epidemiology and Infection.

[34]  D. Tyrrell,et al.  The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers , 1990, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[35]  K. Callow.  Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection , 1985, Journal of Hygiene.

[36]  A. M. Collier,et al.  Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. , 1979, The New England journal of medicine.

[37]  J. Mantle,et al.  An epidemic of influenza on Tristan da Cunha , 1973, Journal of Hygiene.

[38]  D. Tyrrell,et al.  Effects of a "new" human respiratory virus in volunteers. , 1967, British medical journal.

[39]  R. Russell.  Epidemic Influenza , 1893, Nature.